RT Journal Article
SR Electronic
T1 Heterogeneous Sensitivity of Hepatocellular Carcinoma to Sorafenib Revealed by the Short-term Culture of Tumor Fragments
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1415
OP 1420
VO 33
IS 4
A1 GODIN, CORINNE
A1 DUPONT, SEBASTIEN
A1 EZZOUKHRY, ZAKARIA
A1 LOUANDRE, CHRISTOPHE
A1 CHATELAIN, DENIS
A1 HENAUT, LUCIE
A1 SABBAGH, CHARLES
A1 REGIMBEAU, JEAN-MARC
A1 MAZIERE, JEAN-CLAUDE
A1 BARBARE, JEAN-CLAUDE
A1 CHAUFFERT, BRUNO
A1 GALMICHE, ANTOINE
YR 2013
UL http://ar.iiarjournals.org/content/33/4/1415.abstract
AB Background/Aim: Sorafenib is currently the only medical treatment with proven efficacy against hepatocellular carcinoma (HCC). HCC cell lines display heterogeneous sensitivity to sorafenib, but little is known about the sensitivity of clinical tumors. We aimed to examine this aspect. Materials and Methods: Using experimental tumors generated in nude mice, we set up a technique for short-term culture of HCC fragments. We applied this technique to six human HCC samples obtained from surgical resection. Results: HCC fragments in culture retain their morphology and viability for at least 48 h, permitting an in vitro analysis of the effect of sorafenib on the Extracellular signal-regulated kinase (ERK) cascade. HCC exhibit heterogeneous individual responses, ranging from potent inhibition to paradoxical activation of this oncogenic cascade. Conclusion: Our observations highlight the heterogeneous sensitivity of HCC to sorafenib, and point to the potential interest of short-term culture of tumor fragments for personalizing the medical treatment of HCC.